Your browser doesn't support javascript.
loading
Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.
Ahmed, Sameed; Ellis, Miandra; Li, Hongshan; Pallucchini, Luca; Stein, Andrew M.
Afiliação
  • Ahmed S; Department of Applied Mathematics, University of Waterloo, Waterloo, Canada.
  • Ellis M; School of Mathematical and Statistical Sciences, Arizona State University, Tempe, USA.
  • Li H; Department of Mathematics, Purdue University, Lafayette, USA.
  • Pallucchini L; Department of Mathematics, Temple University, Philadelphia, USA.
  • Stein AM; Novartis Institute for BioMedical Research, 45 Sidney St., Cambridge, MA, 02140, USA. andrew.stein@novartis.com.
J Pharmacokinet Pharmacodyn ; 46(3): 287-304, 2019 06.
Article em En | MEDLINE | ID: mdl-31037615
ABSTRACT
Guiding the dose selection for monoclonal antibody oncology drugs is often done using methods for predicting the receptor occupancy of the drug in the tumor. In this manuscript, previous work on characterizing target inhibition at steady state using the AFIR metric (Stein and Ramakrishna in CPT Pharmacomet Syst Pharmacol 6(4)258-266, 2017) is extended to include a "target-tissue" compartment and the shedding of membrane-bound targets. A new potency metric average free tissue target to initial target ratio (AFTIR) at steady state is derived, and it depends on only four key quantities the equilibrium binding constant, the fold-change in target expression at steady state after binding to drug, the biodistribution of target from circulation to target tissue, and the average drug concentration in circulation. The AFTIR metric is useful for guiding dose selection, for efficiently performing sensitivity analyses, and for building intuition for more complex target mediated drug disposition models. In particular, reducing the complex, physiological model to four key parameters needed to predict target inhibition helps to highlight specific parameters that are the most important to estimate in future experiments to guide drug development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá